Search - tctmd.com

Displaying 641 - 660 of 1893

Sort: Relevancy | Date

FDA Gives Rivaroxaban Another VTE-Related Indication

News Daily News

FDA Gives Rivaroxaban Another VTE-Related Indication

October 14, 2019

Study Unearths Gender Disparities in Twitter Influence

News Daily News

Study Unearths Gender Disparities in Twitter Influence

Yael L. Maxwell

October 14, 2019

News TCT 2019

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

September 26, 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

News Conference News TCT 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

September 26, 2019

https://www.tctmd.com/news/ideal-lm-probes-short-dapt-and-bioabsorbable-polymer-stent-left-main-disease

News Conference News TCT 2019

IDEAL-LM Probes Short DAPT and a Bioabsorbable-Polymer Stent in Left Main Disease

Michael O'Riordan

September 26, 2019

From Ceiling Suspension to Eye-Tracking: Innovation Continues for Cath Lab Radiation Protection

News Conference News TCT 2019

From Ceiling Suspension to Eye-Tracking: Innovation Continues for Cath Lab Radiation Protection

Yael L. Maxwell

September 25, 2019

Bleeding on Low-Dose Antithrombotic Therapy a ‘Red Flag’ for New Cancers

News Daily News

Bleeding on Low-Dose Antithrombotic Therapy a ‘Red Flag’ for New Cancers

Yael L. Maxwell

September 20, 2019

Major Bleeding Mostly Early, Not Severe With Rivaroxaban Plus Aspirin in COMPASS

News Daily News

Major Bleeding Mostly Early, Not Severe With Rivaroxaban Plus Aspirin in COMPASS

September 20, 2019

New PROVE-HF Data May Reassure Clinicians of Sacubitril/Valsartan Benefit in HFrEF

News Conference News HFSA 2019

New PROVE-HF Data May Reassure Clinicians of Sacubitril/Valsartan Benefit in HFrEF

September 18, 2019

Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints

News Conference News ESC 2019

Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints

September 11, 2019

LAA Occluders, NOACs Provide Similar Outcomes in High-risk A-fib Patients: PRAGUE-17

News Conference News ESC 2019

LAA Occluders, NOACs Provide Similar Outcomes in High-risk A-fib Patients: PRAGUE-17

September 10, 2019

TRANSIENT: Treatment Timing Inconsequential When STEMI Resolves Before Revascularization

News Conference News ESC 2019

TRANSIENT: Treatment Timing Inconsequential When STEMI Resolves Before Revascularization

September 09, 2019

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

News Conference News ESC 2019

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

September 03, 2019

AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD

News Conference News ESC 2019

AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD

September 02, 2019

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

News Conference News ESC 2019

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

September 01, 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

August 22, 2019

Substantial Increase in PCI Survival Over 10 Years: Single Center

News Daily News

Substantial Increase in PCI Survival Over 10 Years: Single Center

Yael L. Maxwell

August 16, 2019

CT Perfusion Imaging for In-Stent Restenosis Shows Promise

News Daily News

CT Perfusion Imaging for In-Stent Restenosis Shows Promise

Yael L. Maxwell

August 15, 2019

FDA Gives Eagerly Awaited Update on Mortality With Paclitaxel-Coated Devices in PAD

News Daily News

FDA Gives Eagerly Awaited Update on Mortality With Paclitaxel-Coated Devices in PAD

August 07, 2019

Nighttime, 24-Hour BP Readings Have Strongest Link to Poor Outcomes

News Daily News

Nighttime, 24-Hour BP Readings Have Strongest Link to Poor Outcomes

August 06, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.